EcoR1 Capital LLC Buys New Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR

EcoR1 Capital LLC bought a new stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) in the 4th quarter, Holdings Channel.com reports. The fund bought 334,380 shares of the company’s stock, valued at approximately $23,256,000. Structure Therapeutics accounts for about 1.1% of EcoR1 Capital LLC’s investment portfolio, making the stock its 17th largest position.

Several other institutional investors have also recently added to or reduced their stakes in GPCR. Morgan Stanley increased its holdings in Structure Therapeutics by 261.4% in the 4th quarter. Morgan Stanley now owns 2,087,834 shares of the company’s stock valued at $145,209,000 after purchasing an additional 1,510,093 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Structure Therapeutics by 477.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,671,138 shares of the company’s stock valued at $116,228,000 after purchasing an additional 1,381,745 shares during the last quarter. Avoro Capital Advisors LLC increased its holdings in Structure Therapeutics by 21.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 6,555,555 shares of the company’s stock valued at $455,939,000 after purchasing an additional 1,150,000 shares during the last quarter. Capitolis Liquid Global Markets LLC acquired a new stake in Structure Therapeutics in the 4th quarter valued at approximately $61,086,000. Finally, Deutsche Bank AG acquired a new stake in Structure Therapeutics in the 4th quarter valued at approximately $58,503,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Stock Performance

Shares of NASDAQ:GPCR opened at $45.00 on Thursday. The company has a 50-day simple moving average of $43.09 and a 200-day simple moving average of $57.53. Structure Therapeutics Inc. Sponsored ADR has a one year low of $15.80 and a one year high of $94.90. The stock has a market capitalization of $3.20 billion, a price-to-earnings ratio of -51.72 and a beta of -1.35.

Structure Therapeutics (NASDAQ:GPCR) last announced its earnings results on Thursday, May 7th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.04. As a group, research analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -1.64 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on GPCR. Wolfe Research began coverage on shares of Structure Therapeutics in a report on Thursday, March 26th. They issued a “peer perform” rating for the company. Leerink Partners reissued an “outperform” rating on shares of Structure Therapeutics in a research report on Monday, March 16th. Canaccord Genuity Group initiated coverage on shares of Structure Therapeutics in a research report on Monday, April 27th. They issued a “buy” rating and a $101.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Tuesday, April 21st. Finally, Wall Street Zen cut shares of Structure Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $106.75.

Structure Therapeutics Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.